Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
## Sante FX V+\nSante FX V+ is a Japanese over-the-counter ophthalmic combination drug developed and manufactured by Santen for symptomatic relief of eye fatigue and irritation. It is a multi-ingredient small-molecule eye drop containing pyridoxine hydrochloride, taurine, potassium L-aspartate, neostigmine methylsulfate, tetrahydrozoline hydrochloride, chlorpheniramine maleate, and epsilon-aminocaproic acid. The formulation combines nutritional and metabolic support components with a parasympathomimetic agent that can aid accommodative function, a vasoconstrictor that reduces conjunctival hyperemia, an antihistamine that reduces itching and irritation, and an anti-inflammatory or antifibrinolytic component used in ophthalmic irritation. It is marketed in Japan as a cooling eye drop for eye fatigue, conjunctival redness, itchy eyes, prevention of eye diseases, ocular inflammation caused by ultraviolet rays or other light exposure, blurred vision, blepharitis, and discomfort associated with hard contact lens use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sante FX V+.